title: Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
abstract: Oritavancin, a lipoglycopeptide antibiotic, recently received US FDA approval for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Oritavancin, unlike other intravenous antibiotics that are currently available for the treatment of ABSSSI (e.g., vancomycin, daptomycin, telavancin, dalbavancin), offers the option of a single-dose complete regimen. The dosing schedule of oritavancin eliminates the need for an indwelling catheter and introduces the possibility of avoidance of a hospital admission; although, treatment in non-hospital settings has not been adequately evaluated in clinical trials. The availability of oritavancin adds another agent to our antibiotic armamentarium providing dosing flexibility and an alternative treatment option for treatment of ABSSSI caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus.
authors: Department of Pharmacy, New York Methodist Hospital, 506 6th Street, Brooklyn, NY 11215, USA.
authors: Gary
authors: G
authors: Wu
authors: James
authors: J
authors: Truong
authors: Spencer
authors: S
authors: Lee
authors: Ola
authors: O
authors: Elnadoury
authors: William
authors: W
authors: Kuan
authors: Teena
authors: T
authors: Abraham
authors: Anh
authors: A
authors: Wu
authors: Mei
authors: M
authors: Liu
mesh_terms: D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D017277:Drug Approval; D054796:Drug Dosage Calculations; D013293:Enterococcus faecalis / Q000187:drug effects / Q000254:growth & development; D016984:Enterococcus faecium / Q000187:drug effects / Q000254:growth & development; D006020:Glycopeptides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D007275:Injections, Intravenous; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D016032:Randomized Controlled Trials as Topic; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D013291:Streptococcus / Q000187:drug effects / Q000254:growth & development; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin
keywords: acute bacterial skin and skin structure infections; complicated skin and skin structure infections; glycopeptides; lipoglycopeptides; oritavancin